2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Lung Neoplasms
26
Prostatic Neoplasms
24
Breast Neoplasms
17
Carcinoma, Non-Small-Cell Lung
15
Multiple Myeloma
14
Sarcoma
12
Leukemia, Myeloid, Acute
12
Glioma
12
Lymphoma, Non-Hodgkin
10
Carcinoma, Hepatocellular
10
Wilms Tumor
9
Osteosarcoma
9
Colorectal Neoplasms
9
Rectal Neoplasms
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Ovarian Neoplasms
8
Neuroblastoma
8
Neoplasm Metastasis
8
Myelodysplastic Syndromes
8
Rhabdomyosarcoma
7
Rhabdoid Tumor
7
Pancreatic Neoplasms
7
Mouth Neoplasms
7
Medulloblastoma
7
Hepatoblastoma
7
Neuroectodermal Tumors, Primitive, Peripheral
6
Melanoma
6
Lymphoma
6
Histiocytosis, Langerhans-Cell
6
Head and Neck Neoplasms
6
Interventions
Cyclophosphamide
153
Dexamethasone
141
Rituximab
85
fludarabine
79
Lenalidomide
72
Cytarabine
70
Bortezomib
64
fludarabine phosphate
63
Gemcitabine
62
venetoclax
54
Etoposide
53
pomalidomide
52
pembrolizumab
52
Paclitaxel
48
Cisplatin
48
Carboplatin
48
Peripheral Blood Stem Cell Transplantation
47
Filgrastim
40
Radiotherapy
39
Busulfan
37
Calcium Dobesilate
36
Methotrexate
34
Melphalan
34
Bevacizumab
33
carfilzomib
32
Cyclosporine
32
Azacitidine
32
Mycophenolic Acid
30
Vincristine
29
Bendamustine Hydrochloride
29
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
X-Rays
×
Clear all
NCT02636634
2016-04-11
CV-METANEC
Assistance Publique - Hôpitaux de Paris
Phase 3
Completed
90 enrolled